Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 5.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 134,334 shares of the company’s stock after acquiring an additional 6,784 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Dyne Therapeutics were worth $4,825,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Dyne Therapeutics by 69.7% in the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after acquiring an additional 3,707,734 shares during the period. Jennison Associates LLC grew its position in Dyne Therapeutics by 1.5% during the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after purchasing an additional 19,730 shares during the period. Federated Hermes Inc. raised its stake in shares of Dyne Therapeutics by 10.4% during the 2nd quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock valued at $42,881,000 after buying an additional 114,888 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Dyne Therapeutics by 7.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 648,652 shares of the company’s stock valued at $23,300,000 after buying an additional 47,590 shares during the period. Finally, First Light Asset Management LLC boosted its stake in shares of Dyne Therapeutics by 261.0% in the second quarter. First Light Asset Management LLC now owns 382,433 shares of the company’s stock worth $13,496,000 after buying an additional 276,485 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This trade represents a 1.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares of the company’s stock, valued at $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 180,046 shares of company stock valued at $6,300,265. 20.77% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Finally, Guggenheim increased their target price on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.82.

Dyne Therapeutics Stock Down 3.0 %

DYN opened at $27.47 on Thursday. The company has a market cap of $2.80 billion, a PE ratio of -7.72 and a beta of 1.09. Dyne Therapeutics, Inc. has a twelve month low of $10.33 and a twelve month high of $47.45. The company has a 50-day moving average price of $30.68 and a 200 day moving average price of $35.30.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.